NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 356 filers reported holding NEKTAR THERAPEUTICS in Q1 2019. The put-call ratio across all filers is 1.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $30,000 | -41.2% | 1,766 | -20.2% | 0.00% | -33.3% |
| Q2 2020 | $51,000 | +24.4% | 2,213 | -2.7% | 0.01% | 0.0% |
| Q1 2020 | $41,000 | -19.6% | 2,275 | -3.6% | 0.01% | 0.0% |
| Q4 2019 | $51,000 | +10.9% | 2,360 | -7.5% | 0.01% | +20.0% |
| Q3 2019 | $46,000 | -65.2% | 2,551 | -31.6% | 0.01% | -64.3% |
| Q2 2019 | $132,000 | -5.7% | 3,728 | -10.2% | 0.01% | -57.6% |
| Q1 2019 | $140,000 | -5.4% | 4,150 | -7.7% | 0.03% | -8.3% |
| Q4 2018 | $148,000 | -58.8% | 4,497 | -23.7% | 0.04% | -49.3% |
| Q3 2018 | $359,000 | +56.8% | 5,891 | +25.7% | 0.07% | +54.3% |
| Q2 2018 | $229,000 | -52.3% | 4,685 | +3.6% | 0.05% | -54.0% |
| Q1 2018 | $480,000 | +61.1% | 4,524 | -9.2% | 0.10% | +72.4% |
| Q4 2017 | $298,000 | +223.9% | 4,984 | -25.4% | 0.06% | +427.3% |
| Q1 2016 | $92,000 | -31.9% | 6,683 | -16.6% | 0.01% | -21.4% |
| Q4 2015 | $135,000 | 0.0% | 8,013 | -31.2% | 0.01% | +16.7% |
| Q2 2013 | $135,000 | – | 11,650 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 432,952 | $1,385,000 | 0.91% |
| GREAT POINT PARTNERS LLC | 447,820 | $1,433,000 | 0.34% |
| Birchview Capital, LP | 128,000 | $410,000 | 0.29% |
| Edgestream Partners, L.P. | 1,047,636 | $3,352,000 | 0.26% |
| Rhenman & Partners Asset Management AB | 550,000 | $2,068,000 | 0.22% |
| CM Management, LLC | 50,000 | $160,000 | 0.18% |
| TANG CAPITAL MANAGEMENT LLC | 430,037 | $1,376,000 | 0.17% |
| PDT Partners, LLC | 307,953 | $985,000 | 0.15% |
| Virtus ETF Advisers LLC | 72,018 | $230,000 | 0.09% |
| ALGERT GLOBAL LLC | 476,412 | $1,525,000 | 0.09% |